FDA approves study of SNUG01 gene therapy for adults with ALS

FDA approves study of SNUG01 gene therapy for adults with ALS

The U.S. Food and Drug Administration (FDA) has authorized Sineugene Therapeutics to begin a Phase 1/2a trial of its experimental gene therapy, SNUG01, in people with amyotrophic lateral sclerosis (ALS). The global trial will assess the treatment’s safety, tolerability, and preliminary efficacy through a dose escalation and expansion protocol in adults with ALS, according to a company press release. ALS is caused by the progressive dysfunction a…